Your browser is no longer supported. Please, upgrade your browser.
Settings
LIFE aTyr Pharma, Inc. daily Stock Chart
LIFE [NASD]
aTyr Pharma, Inc.
Index- P/E- EPS (ttm)-1.53 Insider Own0.50% Shs Outstand28.43M Perf Week-4.93%
Market Cap19.19M Forward P/E- EPS next Y-0.99 Insider Trans0.00% Shs Float27.75M Perf Month-13.45%
Income-43.70M PEG- EPS next Q-0.31 Inst Own62.50% Short Float3.79% Perf Quarter-23.30%
Sales- P/S- EPS this Y23.50% Inst Trans-0.01% Short Ratio2.05 Perf Half Y-71.88%
Book/sh1.52 P/B0.44 EPS next Y20.80% ROA-52.90% Target Price1.18 Perf Year-86.76%
Cash/sh2.27 P/C0.30 EPS next 5Y- ROE-74.00% 52W Range0.60 - 5.20 Perf YTD-80.71%
Dividend- P/FCF- EPS past 5Y-19.10% ROI- 52W High-87.48% Beta2.90
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin- 52W Low8.39% ATR0.07
Employees58 Current Ratio6.00 Sales Q/Q- Oper. Margin- RSI (14)43.33 Volatility8.36% 10.08%
OptionableYes Debt/Eq0.43 EPS Q/Q31.60% Profit Margin- Rel Volume0.16 Prev Close0.68
ShortableYes LT Debt/Eq0.26 EarningsNov 13 AMC Payout- Avg Volume513.13K Price0.65
Recom2.80 SMA20-12.15% SMA50-10.32% SMA200-63.65% Volume81,792 Change-3.56%
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Sep-07-17Initiated Piper Jaffray Overweight $7
Dec-13-16Downgrade JP Morgan Overweight → Neutral
Dec-16-15Initiated Citigroup Neutral
Jun-01-15Initiated JP Morgan Overweight $44
Jun-01-15Initiated Citigroup Buy $32
Oct-17-18 08:00AM  aTyr Pharma Presents at American Society of Human Genetics 2018 Meeting GlobeNewswire
Oct-15-18 04:30PM  aTyr Pharma Announces Leadership Transition GlobeNewswire
Sep-27-18 04:05PM  aTyr Pharma Announces Pulmonary Sarcoidosis as Disease Indication for Phase 1b/2a Clinical Study and Educational Webinar GlobeNewswire
Sep-20-18 04:38PM  aTyr Pharma to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference GlobeNewswire
Aug-30-18 05:51PM  Edited Transcript of LIFE earnings conference call or presentation 14-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
08:00AM  aTyr Pharma to Present at the Baird 2018 Global Healthcare Conference GlobeNewswire
Aug-14-18 05:03PM  Atyr Pharma: 2Q Earnings Snapshot Associated Press
04:05PM  aTyr Pharma Announces Second Quarter 2018 Operating Results and Provides Corporate Update GlobeNewswire
03:00PM  aTyr Pharma, Inc. to Host Earnings Call ACCESSWIRE
Aug-08-18 04:05PM  aTyr Pharma to Host Conference Call and Webcast of Second Quarter 2018 Financial Results on August 14, 2018 GlobeNewswire
Jul-31-18 08:00AM  aTyr Pharma Appoints Jill Broadfoot as Chief Financial Officer GlobeNewswire
Jul-26-18 08:00AM  aTyr Pharma Presents Positive Lung and Skin Findings with ATYR1923 in a Translational Animal Model at the Scleroderma Foundation National Patient Education Conference GlobeNewswire
Jun-26-18 08:00AM  aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate GlobeNewswire -8.18%
Jun-08-18 01:46PM  Edited Transcript of LIFE earnings conference call or presentation 19-Mar-18 9:00pm GMT Thomson Reuters StreetEvents +14.44%
May-31-18 08:00AM  aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-17-18 07:30AM  aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference GlobeNewswire +14.71%
May-15-18 08:06AM  Edited Transcript of LIFE earnings conference call or presentation 14-May-18 12:00pm GMT Thomson Reuters StreetEvents -12.90%
May-14-18 06:49AM  Atyr Pharma: 1Q Earnings Snapshot Associated Press -32.61%
06:45AM  aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring GlobeNewswire
06:00AM  aTyr Pharma, Inc. to Host Earnings Call ACCESSWIRE
May-08-18 08:00AM  aTyr Pharma to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 14, 2018 GlobeNewswire
May-02-18 08:00AM  aTyr Pharma Provides Mechanistic Update on Resokine Pathway at American Academy of Immunology Annual Meeting GlobeNewswire
Mar-26-18 08:14AM  aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy? Zacks
Mar-19-18 04:37PM  Atyr Pharma reports 4Q loss Associated Press
04:05PM  aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update GlobeNewswire
12:30PM  aTyr Pharma, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-18 08:00AM  aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018 GlobeNewswire
Mar-01-18 08:00AM  aTyr Pharma to Present at Two Upcoming Investor Conferences in March GlobeNewswire
Dec-21-17 08:00AM  aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire
Dec-07-17 08:00AM  aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-27-17 08:00AM  aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923) GlobeNewswire +8.75%
Nov-21-17 08:00AM  aTyr Pharma to Participate at the Piper Jaffray 29th Annual Healthcare Conference GlobeNewswire
Nov-16-17 05:14AM  Atyr Pharma reports 3Q loss Associated Press
Nov-14-17 04:05PM  aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update GlobeNewswire
Nov-01-17 04:05PM  aTyr Pharma Announces Leadership Transition GlobeNewswire -16.67%
Oct-11-17 08:25AM  Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences Zacks +11.50%
Oct-04-17 08:16PM  How Should You Think About aTyr Pharma Incs (LIFE) Risks? Simply Wall St. +18.95%
Sep-27-17 08:00AM  aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society GlobeNewswire +9.52%
Sep-05-17 11:00PM  aTyr Pharma to Present at Two Upcoming Investor Conferences in September GlobeNewswire -9.84%
Aug-28-17 06:24PM  [$$] Publicly Traded Rare Disease Drug-Maker aTyr Pharma Gets $46 Million Lift The Wall Street Journal +5.77%
07:30AM  aTyr Pharma Announces $45 Million Equity Financing GlobeNewswire
Aug-14-17 11:24PM  Atyr Pharma reports 2Q loss Associated Press +6.56%
04:05PM  aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline GlobeNewswire
Aug-10-17 08:45AM  aTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results GlobeNewswire
May-31-17 09:00AM  aTyr Pharma to Present at Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-15-17 08:00AM  aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar GlobeNewswire
May-11-17 05:51PM  Atyr Pharma reports 1Q loss Associated Press
04:05PM  aTyr Pharma Announces First Quarter 2017 Operating Results GlobeNewswire
Apr-24-17 08:00AM  aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting GlobeNewswire
07:30AM  aTyr Pharma Announces Promising Top-Line Results from Resolaris Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular Dystrophy GlobeNewswire
Apr-10-17 05:00PM  aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors GlobeNewswire
Apr-03-17 08:02AM  ATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers
08:00AM  aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors PR Newswire
Mar-29-17 09:00AM  aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference GlobeNewswire
Mar-22-17 01:04PM  ATYR PHARMA INC Financials -5.48%
Mar-16-17 04:46PM  Atyr Pharma reports 4Q loss Associated Press +7.04%
04:12PM  ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Mar-15-17 06:00AM  aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived From 20 out of 20 Human tRNA Synthetases PR Newswire
Mar-03-17 08:00AM  aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris PR Newswire
Mar-01-17 12:30PM  aTyr Pharma Rises 16% on Orphan Drug Status Investopedia -6.25%
12:30PM  aTyr Pharma Rises 16% on Orphan Drug Status at Investopedia
08:00AM  aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference PR Newswire
Feb-28-17 08:00AM  aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris PR Newswire +15.94%
Feb-22-17 12:49PM  High court ruling limits international reach of patent laws Associated Press
12:49PM  High court ruling limits international reach of patent laws
Jan-19-17 12:00PM  Atyr Pharma Stock Spikes 33% on FDA Updates at Investopedia -7.69%
Jan-18-17 08:00AM  FDA Grants Fast Track Designation for aTyr's Resolaris to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris PR Newswire +32.65%
Jan-09-17 09:03AM  ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure
Jan-04-17 06:05PM  Roberts recuses from patent case after discovering conflict
Dec-21-16 01:15PM  Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares +6.98%
Dec-16-16 10:07PM  Does aTyr Pharma Inc (LIFE) Stack Up Against Its Peers? at Insider Monkey
Dec-13-16 12:20PM  aTyr Pharma downgraded by JP Morgan -23.29%
10:45AM  aTyr Pharma Drops on Clinical Update
07:02AM  ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events
07:00AM  aTyr Pharma Reports Promising Signals of Clinical Activity in Multiple Rare Genetically Distinct Myopathies with Resolaris in Exploratory Trials PR Newswire
Dec-09-16 09:00AM  aTyr Pharma to Present at the BMO Prescriptions for Success Healthcare Conference PR Newswire
Dec-05-16 11:39AM  aTyr Pharma, Inc. :LIFE-US: Earnings Analysis: Q3, 2016 By the Numbers : December 5, 2016 +6.56%
Nov-21-16 08:01AM  ATYR PHARMA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive -5.33%
08:00AM  aTyr Pharma Enters into $20 Million Credit Facility PR Newswire
Nov-18-16 08:40AM  aTyr Pharma (LIFE) Looks Good: Stock Adds 5.9% in Session
Nov-14-16 07:43AM  Atyr Pharma reports 3Q loss +11.11%
07:31AM  ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:30AM  aTyr Pharma Announces Third Quarter 2016 Operating Results PR Newswire
Nov-07-16 09:02AM  ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure
Oct-26-16 12:00PM  aTyr Pharma Receives Fast Track Designation (LIFE) at Investopedia
Oct-24-16 10:15AM  aTyr Receives FDA Fast Track Designation +5.17%
08:00AM  aTyr Pharma Receives FDA Fast Track Designation for Resolaris to Treat Facioscapulohumeral Muscular Dystrophy (FSHD) PR Newswire
Oct-10-16 08:56PM  BMO Sets $8 Target for Atyr Pharma (LIFE) at Investopedia
Oct-06-16 09:06AM  ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events
09:00AM  aTyr Pharma Presents Additional Data for Resolaris Phase 1b/2 Trial in Adult Patients with Facioscapulohumeral Muscular Dystrophy at the 21st International Annual Congress of the World Muscle Society PR Newswire
Sep-29-16 07:50PM  Gershman of aTyr Pharma to Speak on Muscular Dystrophy (LIFE) at Investopedia
08:30AM  aTyr Pharma Announces Presentation at the 21st International Annual Congress of the World Muscle Society PR Newswire
Sep-21-16 05:00PM  aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research PR Newswire
Sep-15-16 06:06AM  7 Stocks Under $10 Making Big Moves Higher
Aug-10-16 04:18PM  ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:15PM  Atyr Pharma reports 2Q loss
04:05PM  aTyr Pharma Announces Second Quarter 2016 Operating Results PR Newswire
Jun-16-16 05:17PM  ATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers
Jun-10-16 05:01PM  aTyr Pharma, Inc. :LIFE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016
Jun-03-16 07:30AM  aTyr Pharma to Present at Jefferies 2016 Healthcare Conference PR Newswire
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California.